The Latest Breaking News from Moderna

A new study from the Center for Disease Control and Prevention confirms what Mayo Clinic and other experts have been saying: COVID-19 booster vaccinations improve protection against severe illness and hospitalization. The study examined people who had three doses of the Moderna or Pfizer COVID-19 vaccines, as well as whether…

WASHINGTON — Moderna Inc.’s vaccine for COVID-19 received full approval from the U.S. Food and Drug Administration for people 18 and older, an important milestone that bolsters the shot’s use as a major weapon against the virus.

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 18 strange trades.

Sajid Javid says says mandatory jabs were ‘right policy at the time’ but announces review

The same mRNA technology that’s helping us fight COVID provided a formula that’s evaded scientists for 40 years.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Moderna Inc (NASDAQ: MRNA) has started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically 

US biotech company Moderna announced on Wednesday that it has begun clinical trials of a booster dose of vaccine designed specifically to combat the Omicron variant of the coronavirus.

Protection against death increases to around 95% two weeks after receiving a booster dose, UK health agency says; UK reports another 96,871 Covid cases